Patents by Inventor Bernd Dusterberg
Bernd Dusterberg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20090023693Abstract: The present invention relates to a pharmaceutical combination product with at least 21 daily consecutive dosage units containing from 2.0 mg to 3.0 mg of drospirenone and 1.0 to 2.0 mg of 17?-estradiol in each daily dosage unit followed by intermittent daily dosage units containing the same or smaller amount of drospirenone (i.e. 0.5 mg to 3.0 mg) as the consecutive daily dosage units wherein each intermittent daily dosage unit is preceded by at least one day without administration of drospirenone. These pharmaceutical combination products can be used for female oral contraception, guarantee a withdrawal bleeding each 4 weeks and allow for the full maintenance of the drospirenone related benefits.Type: ApplicationFiled: April 7, 2008Publication date: January 22, 2009Inventors: Vladimir HANES, Hartnut Blode, Rolf Schurmann, Bernd Dusterberg, Joachim Marr
-
Publication number: 20080234240Abstract: A pharmaceutical preparation to obtain a continuous hormonal treatment over a desired period of time longer than 21-28 days comprising a first composition containing at least one estrogen and/or at least one progestin in a predetermined amount to be administered in the first 21-28 days and a second composition which contains at least one estrogen and/or at least one progestin in a predetermined amount higher than the amount of the first composition and comprises a mono or multiphase sequence of pharmaceutical dosages.Type: ApplicationFiled: November 20, 2004Publication date: September 25, 2008Applicant: SCHERING AGInventors: Bernd Düsterberg, Jan Endrikat, Rolf Schurmann
-
Contraceptive process and kit for female mammals, comprising a combination of gestagen and oestrogen
Patent number: 6995149Abstract: The present invention relates to a female mammal contraceptive process consisting of the sequential administration for at least 28 days of (a) a gestagen in an ovulation-preventing dose for at least 28 days in combination with (b) a natural oestrogen for 5 to 10 days at the end of the sequential dosage of at least 28 days, and a contraception kit.Type: GrantFiled: December 20, 1996Date of Patent: February 7, 2006Assignee: Schering AGInventors: Jan Endrikat, Bernd Düsterberg, Pia Reilhac -
Patent number: 5980940Abstract: The invention provides a pharmaceutical combination preparation with two hormone components in a packaging unit and intended for time-sequential oral administration, comprising a number of daily dosage units physically separate and individually removable in the packaging unit, whereby as a hormonal active ingredient a first hormone component contains in combination an estrogen preparation and in at least a dosage that is sufficient to inhibit ovulation a gestagen preparation, and as a hormonal active ingredient the second hormone component contains only an estrogen preparation, whereby the first hormone component comprises 23 or 24 daily units and the second hormone component comprises 4, 3 or 2 daily units, and between these two hormone components, 2 or 1 active ingredient-free daily units are present or 2 or 1 blank pill days are indicated, and the total number of hormone daily units and the active ingredient-free daily units or the blank pill days is equal to the total number of days of the desired cycle,Type: GrantFiled: January 27, 1998Date of Patent: November 9, 1999Assignee: Schering AGInventors: Jurgen Spona, Bernd Dusterberg
-
Patent number: 5824667Abstract: A combination product for oral contraception is disclosed comprising an estrogen selected from2.0 to 6.0 mg of 17.beta.-estradiol and0.020 mg of ethinylestradiol;and a gestagen selected from0.25 to 0.30 mg of drospirenone and0.1 to 0.2 mg of cyproterone acetate,followed by 5 or 4 pill-free or sugar pill days.Type: GrantFiled: October 31, 1996Date of Patent: October 20, 1998Assignee: Schering AktiengesellschaftInventors: Jurgen Spona, Bernd Dusterberg, Frank Ludicke
-
Patent number: 5756490Abstract: A pharmaceutical combination preparation with two hormone components that are manufactured physically separately in a packaging unit and that are intended for time-sequential oral administration, which in each case consist of a number of daily dosage units that are placed physically separately and are individually removable in the packaging unit. As a hormonal active ingredient, a first hormone component contains in combination an estrogen preparation and, in at least a dosage that is sufficient to inhibit ovulation, a gestagen preparation, and as a hormonal active ingredient the second hormone component contains only an estrogen preparation. The first hormone component comprises 23 or 24 daily units and the second hormone component comprises 4 to 10 daily units. The total number of hormone daily units is equal to the total number of days of the desired cycle, but at least 28 days in length.Type: GrantFiled: December 16, 1996Date of Patent: May 26, 1998Assignee: Schering AktiengesellschaftInventors: Ursula Lachnit, Bernd Dusterberg, Jurgen Spona
-
Patent number: 4794119Abstract: An aqueous crystalline suspension of a 17-tertiary steroid glycoester contains a compound of Formula I ##STR1## wherein X is two hydrogen atoms or an oxygen atom,Y is two hydrogen atoms or a methylene group,R.sup.1 is hydrogen or methyl,Z is hydroxy or --O--CO--R.sup.2R.sup.2 is methyl or phenyl, and ##STR2## in the following fractions: 0-30% by weight of a particle size of 3-15 .mu.m,40-90% by weight of a particle size of 15-60 .mu.m, and20-60% by weight of a particle size of 30-100 .mu.m.Upon a one-time intramuscular injection of 30-75 mg of steroid glycoester as an aqueous crystalline suspension, a steroid level is achieved in the plasma which, over a period of 4 weeks, is adequately high and shows a uniform course.Type: GrantFiled: March 27, 1986Date of Patent: December 27, 1988Assignee: Schering AktiengesellschaftInventors: Paul-Eberhard Schulze, Bernard Acksteiner, Bernd Dusterberg
-
Patent number: RE37564Abstract: A combination product for oral contraception is disclosed comprising an estrogen selected from 2.0 to 6.0 mg of 17&bgr;-estradiol and 0.020 mg of ethinylestradiol; and a gestagen selected from 0.25 to 0.30 2.5 to 3.0 mg of drospirenone and 0.1 to 0.2 1 to 2 mg of cyproterone acetate, followed by 5 or 4 pill-free or sugar pill days.Type: GrantFiled: February 15, 2000Date of Patent: February 26, 2002Assignee: Schering AktiengesellschaftInventors: Jürgen Spona, Bernd Düsterberg, Frank Lüdicke
-
Patent number: RE37838Abstract: A combination product for oral contraception is disclosed comprising an estrogen selected from 2.0 to 6.0 mg of 17&bgr;-estradiol and 0.020 mg of ethinylestradiol; and a gestagen selected from 0.25 to 0.30 mg of drospirenone and 0.1 to 0.2 mg of cyproterone acetate, followed by 5 or 4 pill-free or sugar pill days.Type: GrantFiled: February 15, 2000Date of Patent: September 10, 2002Assignee: Schering AktiengesellschaftInventors: Jürgen Spona, Bernd Düsterberg, Frank Lüdicke
-
Patent number: RE38253Abstract: A combination product for oral contraception is disclosed comprising an estrogen selected from 2.0 to 6.0 mg of 17&bgr;-estradiol and 0.020 mg of ethinylestradiol; and a gestagen selected from 0.25 to 0.30 2.5 to 3.0 mg of drospirenone and 0.1 to 0.2 1 to 2 mg of cyproterone acetate, followed by 5 or 4 pill-free or sugar pill days.Type: GrantFiled: February 25, 2002Date of Patent: September 16, 2003Assignee: Schering AktiengesellschaftInventors: Jürgen Spona, Bernd Düsterberg, Frank Lüdicke
-
Patent number: RE43916Abstract: A combination product for oral contraception is disclosed comprising an estrogen selected from 2.0 to 6.0 mg of 17?-estradiol and 0.020 mg of ethinylestradiol; and a gestagen selected from 0.25 to 0.30 mg of drospirenone and 0.1 to 0.2 mg of cyproterone acetate, followed by 5 or 4 pill-free or sugar pill days.Type: GrantFiled: March 24, 2006Date of Patent: January 8, 2013Assignee: Bayer Schering Pharma AktiengesellschaftInventors: Jurgen Spona, Bernd Dusterberg, Frank Ludicke
-
Patent number: RE44159Abstract: A combination product for oral contraception is disclosed comprising an estrogen selected from 2.0 to 6.0 mg of 17?-estradiol and 0.020 mg of ethinylestradiol; and a gestagen selected from 0.25 to 0.30 mg of drospirenone and 0.1 to 0.2 mg of cyproterone acetate, followed by 5 or 4 pill-free or sugar pill days.Type: GrantFiled: August 28, 2007Date of Patent: April 16, 2013Assignee: Bayer Schering Pharma AktiengesellschaftInventors: Jurgen Spona, Bernd Dusterberg, Frank Ludicke